## Mehrdad Rakaee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6740413/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer. Carcinogenesis, 2021, 42, 685-693.	1.3	10
2	Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. British Journal of Cancer, 2021, 124, 1680-1689.	2.9	37
3	High expression of miR-17-5p in tumor epithelium is a predictor for poor prognosis for prostate cancer patients. Scientific Reports, 2021, 11, 13864.	1.6	21
4	Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancer—A Multi-Institutional Study. Cancers, 2021, 13, 4096.	1.7	11
5	Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis. Autoimmunity Reviews, 2021, 20, 102980.	2.5	35
6	Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?. Carcinogenesis, 2020, 41, 1671-1681.	1.3	18
7	Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC. Scientific Reports, 2019, 9, 10163.	1.6	20
8	Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. Scientific Reports, 2019, 9, 10662.	1.6	32
9	MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. Scientific Reports, 2019, 9, 386.	1.6	43
10	Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry. Neoplasia, 2019, 21, 282-293.	2.3	117
11	LAG-3 in Non–Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival. Clinical Lung Cancer, 2018, 19, 249-259.e2.	1.1	48
12	Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non–small cell lung cancer. Human Pathology, 2018, 79, 188-198.	1.1	49
13	Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer. PLoS ONE, 2018, 13, e0192157.	1.1	35
14	High expression of PDGFR-Î <sup>2</sup> in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence. Scientific Reports, 2017, 7, 43378.	1.6	51
15	CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunology, Immunotherapy, 2017, 66, 1449-1461.	2.0	69
16	Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort. PLoS ONE, 2017, 12, e0186852.	1.1	39
17	Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer. PLoS ONE, 2017, 12, e0189000.	1.1	2
18	Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer. Oncotarget, 2016, 7, 72184-72196.	0.8	54